Strokes caused by an artery tear are landing five times as many Americans in the hospital these days, a new study says.

A change in the monetary system presages a commodity bull market. Not only gold, but commodities generally will likely respond positively to what’s underway, advises Adrian Day, editor of Global ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Even statins don’t work on risk factor called lipoprotein (a) that quickly clings to arteries and narrows them ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

Eli Lilly rolled out positive Phase 2 results for lepodisiran, a therapy targeting lipoprotein(a)—that genetic party crasher ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy.

Inherited or genetic heart disorders, mostly known as Hypertrophic cardiomyopathy (HCM) in medical term, is a condition affecting the left ventricle, the main p ...

A single dose of an experimental drug has been found to reduce the risk of genetic heart disease by at least 94 per cent.

Eli Lilly and Company announced encouraging results from a Phase 2 trial of lepodisiran, an investigational therapy aimed at ...

New drug shows promise in lowering Lp(a), a hidden heart risk factor. Especially vital for Black Americans, who often have ...